Charles Ruggeroli, MD
Cardiovascular Disease · Las Vegas, NVNPI 1518907401
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,540 of the $7,812 with a category attached, or 70.9%. 34 manufacturers reported payments, led by Novartis at 39.2% of the total. Reporting peaked in 2019 at $4,155 and has fallen 88.3% since, to $485 in 2025.
Across 307 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3K
- Amgen$797
- Johnson & Johnson$442
- Sanofi-aventis U.S. LLC$405
- Boehringer Ingelheim$302
- E.r. Squibb & Sons, L.L.C.$284
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$2,24029%
- Food & beverage$5,54071%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 45 | $3,058 |
| Amgen | 50 | $797 |
| Johnson & Johnson | 31 | $442 |
| Sanofi-aventis U.S. LLC | 20 | $405 |
| Boehringer Ingelheim | 17 | $302 |
| E.r. Squibb & Sons, L.L.C. | 17 | $284 |
| AstraZeneca | 15 | $248 |
| Abbott | 12 | $235 |
| Actelion Pharmaceuticals US, Inc. | 8 | $175 |
| Cvrx, Inc. | 10 | $166 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $153 |
| Merck | 7 | $149 |
| Novo Nordisk | 8 | $137 |
| Bayer | 7 | $132 |
| Arbor Pharmaceuticals, Inc. | 7 | $115 |
| Amarin Pharma, Inc. | 6 | $112 |
| Philips North America LLC | 1 | $103 |
| Boston Scientific | 5 | $96 |
| Lexicon Pharmaceuticals, Inc. | 5 | $87 |
| Regeneron Healthcare Solutions, Inc. | 4 | $87 |
| Astellas Pharma US Inc | 5 | $80 |
| Pfizer | 4 | $57 |
| Kowa Pharmaceuticals America, Inc. | 3 | $56 |
| Bard Peripheral Vascular, Inc. | 1 | $55 |
| Irhythm Technologies, Inc. | 2 | $49 |
| Alnylam Pharmaceuticals Inc. | 2 | $47 |
| Portola Pharmaceuticals, LLC | 3 | $37 |
| Medtronic | 2 | $32 |
| Bridgebio Pharma, Inc. | 1 | $30 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Edwards Lifesciences | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$2,341
- (5044) MCOT$103
How this compares
$7,812 in reported general payments places this provider in the 70th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 485 | $495,781 |
| EntrestoSacubitril/Valsartan | 214 | $235,408 |
| Repatha SureclickEvolocumab | 232 | $201,344 |
| XareltoRivaroxaban | 152 | $140,743 |
| MultaqDronedarone Hcl | 27 | $48,241 |
| MounjaroTirzepatide | 15 | $21,710 |
| FarxigaDapagliflozin Propanediol | 36 | $21,427 |
| OzempicSemaglutide | 19 | $19,752 |
| VascepaIcosapent Ethyl | 23 | $16,675 |
| Praluent PenAlirocumab | 20 | $15,490 |
| Ambrisentan | 12 | $14,925 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $12,353 |
| BrilintaTicagrelor | 22 | $9,675 |
| Ezetimibe | 297 | $7,616 |
| JardianceEmpagliflozin | 11 | $6,648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $57 | $495,781485 claims |
| NovartisEntresto | $3,058 | $235,408214 claims |
| Johnson & JohnsonXarelto | $442 | $140,743152 claims |
| Sanofi-aventis U.S. LLCMultaq | $405 | $48,24127 claims |
| AstraZenecaFarxiga, Brilinta | $248 | $31,10258 claims |
| Novo NordiskOzempic | $137 | $19,75219 claims |
| Boehringer IngelheimJardiance | $302 | $6,64811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Las Vegas
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
- Jawad KianiLas Vegas$73K
- Amish PrasadLas Vegas$58K
- Chowdhury AhsanLas Vegas$41K
- Sanjay MalhotraLas Vegas$41K
- William ReshLas Vegas$39K
- Ali NamaziLas Vegas$38K
- Herbert Cordero YordanLas Vegas$38K
- Alfred DanielianLas Vegas$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.